Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 27, 2015BMC Pulmonary MedicineOpen Access

Important prognostic factors for survival in patients with malignant pleural effusion

View Full Paper
Ask AI
Bookmark
Share

Key result

ECOG performance status linked to ~74-fold worse survival in malignant pleural effusion at initial diagnosis.

  • HR 73.58
  • 95% CI 23.44-230.95
  • P<0.0001
  • n=165

Why the study?

The approach to palliative treatment of malignant pleural effusion should be individualized due to generally poor survival, but prognostic factors for survival time were not well defined.

Design

Retrospective descriptive observational study

Follow-up

Median 5 months (range 1.0-96.0 months)

Authors

MZMauro ZamboniCSCyro Teixeira da SilvaRBRodrigo Baretta

Discussion

Loading...

Member takes

Overview

May help individualize MPE palliative care; leaves open prospective validation of the prognostic model.

Study Design

Type

Observational (n=165)

Multicenter

No

Structured PICO

P
Population
165 patients with malignant pleural effusion and a confirmed cancer diagnosis, followed from pathological diagnosis to death, with a median overall survival of 5 months.
O
Outcome
Survival time (defined as the time from pathological diagnosis to death)hard clinical

Main Result

Hazard Ratio: 73.58 (95% CI 23.44–230.95)

p-value: p=<0.0001

ECOG performance status is a strong independent predictor of survival in patients with malignant pleural effusion, which can help guide palliative treatment decisions.

Limitations

  • Data originated from a single referral center
  • Retrospective study design
  • Small number of patients in some categories
  • Lack of patients with mesothelioma in the cohort

Cite This Study

Zamboni et al. (2015) conducted an observational in Malignant pleural effusion (n=165). ECOG Performance Status was evaluated on Survival time (HR 73.58, 95% CI 23.44-230.95, p=<0.0001). ECOG Performance Status is a strong independent predictor of survival in patients with malignant pleural effusion at initial diagnosis (HR 73.58).

synapsesocial.com/papers/6aaa4dcee00150b4b5083cebhttps://doi.org/10.1186/s12890-015-0025-z
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of prognostic scores and factors affecting survival in patients with malignant pleural effusion2026
  2. 2Prognostic factors of malignant pleural effusion among palliative care outpatients: A retrospective study2018 · 8 citations
  3. 3Retrospective cohort study of survival length in malignant pleural effusion between 2015 and 20232025
  4. 4Definitive Pleural Interventions and Survival in Malignant Pleural Effusion2026
  5. 5Malignant pleural effusions: Are we better than the past?2024